Stock TRAW TRAWS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq
Other stock markets
 02:00:00 10/05/2024 am IST 		5-day change 1st Jan Change
0.649 USD -0.21% Intraday chart for Traws Pharma, Inc. +1.15% -12.96%
07/05 Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy CI
04/04 North American Morning Briefing : Focus Turns to -2- DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Traws Pharma, Inc. Announces Chief Executive Office Changes
Traws Pharma, Inc. Announces Board Changes
Onconova Therapeutics Shares Drop; Company to Merge With Trawsfynydd Therapeutics
Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc
Onconova Therapeutics, Inc. completed the acquisition of Trawsfynydd Therapeutics, Inc.
Onconova Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
Onconova Therapeutics? Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i?s
Onconova Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer
Onconova Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
Onconova Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Onconova Therapeutics Doses First Patient in Clinical Trial of Endometrial Cancer Combination Therapy
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
Top Midday Gainers
Onconova Therapeutics Chief Medical Officer Mark Gelder Dies Unexpectedly
Onconova Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. News Traws Pharma, Inc.
  5. Other languages
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW